Alexandra Gerlach, Associate Editor

INCA033989 is a monoclonal antibody that selectively targets mutant calreticulin oncogenic function.

The decision is based on positive results from the phase 3 LAURA trial.

Artificial intelligence shows promise in improving diagnosis and treatment for patients with multiple myeloma.

Early diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) may mitigate progression.

Researchers found that PF4/Cxcl4, a key driver of fibrosis, was up regulated on all proteomes.

Erin McConnell, PharmD, discusses the importance of effective cholesterol management for preventing heart disease.

The decision expands treatment options for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM).

Shifting from a vertical, isolated care model into a collaborative approach can improve the clinician and patient experience.

Luspatercept reduced the need for transfusion in patients with myelofibrosis (MF).

Patients with for HER2-positive breast cancer have an increased risk of developing brain tumors.

The humanized anti-butyrophilin 3A monoclonal antibody selectively activates Vγ9Vδ2 T-cells.

The approval is based on positive results from the phase 2/3 IND.227/KEYNOTE-483 trial.

The treatment significantly reduced risk of occurrence by 25% compared with endocrine therapy alone.

Ten-year follow up data showed a sustained survival benefit with nivolumab-ipilimumab in advanced melanoma.

Lebrikizumab (Ebglyss; Eli and Lilly Company) is a monthly maintenance injection with proven efficacy in adults and children aged 12 to 18 years.

Exposure to high cholesterol levels is a significant risk factor for atherosclerosis cardiovascular disease.

Researchers suggest prior treatments and follow-up duration may play a larger role.

Parents of children with cancer had the highest risk of developing mental illness and cardiovascular diseases.

Experts debate over the most effective treatment pathway for Richter transformation, highlighting the risks and benefits of different cellular therapies.

Treatment advancements highlight the curative potential of bone marrow transplants and emerging gene therapies.

The evolving treatment landscape for multiple myeloma includes debates on the timing and effectiveness of CAR T-cell therapy and quadruple immunotherapy regimens.

Optimizing outcomes for patients with chronic myeloid leukemia (CML) requires personalized treatment, adaptive dosing, and precise genetic insights.

New insights into heart failure risks in Native American communities are highlighting the need to address social determinants of health.

Pharmacists can enhance ASCVD management by supporting patient adherence through the administration and monitoring of inclisiran.

Mary McGann, PharmD, BCOP, offers insights into CAR T-cell therapy and the crucial role of pharmacists in mitigating resistance.

Pharmacists play a crucial role in supporting patients with HR+/HER2– breast cancer.

Accurate, effective screening is crucial for connecting patients with needed financial resources and support.

Patients can face barriers to BCMA-targeted treatments.

Pharmacists can be essential sources of education for patients, offering them guidance on safe use and proper dosage.

Palliative care is crucial for safe and effective medication management to relieve symptoms and improve quality of life.